Takeda Pharmaceutical (NYSE:TAK) Raised to Hold at Zacks Research

Key Points

• Zacks Research upgraded Takeda Pharmaceutical to “Hold” from “Strong Sell.” The broader analyst consensus is also “Hold,” with two Buy, one Hold, and one Sell rating.
• Takeda shares opened at $16.72, up 1.0%, with a market capitalization of $53.57 billion. The company reported quarterly revenue of $6.90 billion and earnings per share of $0.56.
• Institutional ownership stands at 9.17%, with several investment firms increasing their stakes in the latest reported periods.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was upgraded by stock analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other research firms have also weighed in on TAK. Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Saturday, July 18th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a "market perform" rating to an "outperform" rating in a research report on Wednesday, April 8th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold".

Takeda Pharmaceutical Trading Up 1.0%

Shares of Takeda Pharmaceutical stock opened at $16.72 on Tuesday. The stock has a market capitalization of $53.57 billion, a PE ratio of 49.17 and a beta of -0.08. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $18.90. The stock has a 50 day moving average price of $16.30 and a two-hundred day moving average price of $17.09. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.60 and a current ratio of 1.14.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $6.90 billion for the quarter. As a group, equities analysts anticipate that Takeda Pharmaceutical will post 3.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. Private Trust Co. NA grew its position in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock worth $27,000 after purchasing an additional 783 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock worth $40,000 after buying an additional 1,684 shares in the last quarter. SHP Wealth Management purchased a new position in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $42,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company's stock worth $48,000 after buying an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock valued at $55,000 after acquiring an additional 1,292 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source